<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524472</url>
  </required_header>
  <id_info>
    <org_study_id>07-470</org_study_id>
    <nct_id>NCT00524472</nct_id>
  </id_info>
  <brief_title>Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery</brief_title>
  <official_title>The Effect of Hyperinsulinemic Glucose Control on Outcomes Following Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing cardiac surgery will be randomized into one of two groups. Group A will
      be administered insulin using the hyperinsulinemic-normoglycemic clamp to normalize blood
      glucose levels intra-operatively. Group B will be administered insulin at the standard of
      care levels established by the participating institution. Patients will be followed at 10
      days, 15 days and one year post-operatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a randomized, controlled design, we propose to test the primary hypothesis that
      normalization of blood glucose using a hyperinsulinemic-normoglycemic clamp technique reduces
      the risk of a composite outcome (one or more) of 30-day postoperative mortality and serious
      postoperative cardiac, renal, neurologic, and infectious postoperative complications in
      patients undergoing cardiac surgery.

      Our secondary hypothesis is that hyperinsulinemic normoglycemic therapy will reduce length of
      stay in intensive care unit, atrial dysrhythmias, creatinine elevation, hospital readmission,
      all-cause and cardiac one-year mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2007</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any Major Morbidity/30-day Mortality</measure>
    <time_frame>within 30 days post surgery</time_frame>
    <description>a composite (any versus none) of the following major postoperative complications occurring:
all-cause postoperative mortality
failure to wean from cardiopulmonary bypass or postoperative low cardiac index requiring mechanical circulatory support with intraaortic balloon counterpulsation, ventricular assist device, and/or extracorporeal mechanical oxygenation
serious postoperative infection
acute postoperative kidney injury requiring renal replacement therapy;
new postoperative focal or global neurologic deficit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post Operative Atrial Fibrillation</measure>
    <time_frame>15 - 30 days post operative</time_frame>
    <description>Evidence suggests that maintaining intra-operative normoglycemia during cardiac surgery while providing exogenous glucose and high-dose insulin may decrease post-operative morbidity or mortality. Using a randomized, controlled design, we propose to test the primary hypothesis that normalization of blood glucose using a hyperinsulinemic-normoglycemic clamp technique reduces the risk of a composite of serious adverse outcomes in patients undergoing cardiac surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>starting post operative day one to discharge from hospital, on an average of 8 days</time_frame>
    <description>Days from date of surgery to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Intensive Care Stay</measure>
    <time_frame>ICU stay hours during hospital stay after surgery, on average of 25 hours</time_frame>
    <description>Hours from date of surgery to discharge from intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>one year post operative</time_frame>
    <description>All-cause mortality identified during one-year follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a Composite of Minor Postoperative Complications</measure>
    <time_frame>within 30 days after surgery</time_frame>
    <description>a composite of minor postoperative complications, which includes: a) prolonged mechanical ventilation, b) low cardiac index, c) acute kidney injury, d) prolonged hospitalization, and 3) all-cause hospital readmission within 30 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1439</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Hyperinsulinemic-normoglycemic clamp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin at the standard of care levels</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group B will be administered insulin at the standard of care levels established by the participating institution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperinsulinemic-normoglycemic clamp</intervention_name>
    <description>Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.</description>
    <arm_group_label>Hyperinsulinemic-normoglycemic clamp</arm_group_label>
    <other_name>clamp</other_name>
    <other_name>Hyperinsulinemic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>insulin at the standard of care levels</intervention_name>
    <description>Subjects will be administered insulin at the standard of care levels established by the participating institution.</description>
    <arm_group_label>Insulin at the standard of care levels</arm_group_label>
    <other_name>insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-90 years old

          -  Scheduled for cardiac surgery requiring cardiopulmonary bypass

        Exclusion Criteria:

          -  Off-pump surgical procedures

          -  Anticipated deep hypothermic circulatory arrest

          -  In available, baseline cardiac troponin I (&gt;0.5 ng/L) or troponin T (&gt; 0.1 ng/mL)
             levels (at RVH or CC, respectively)

          -  Any contraindications to the proposed interventions

          -  Active infection, including patients with endocarditis or infected pacemaker leads.

          -  Any infection requiring long- term antibiotics ( &gt; 14 days)

          -  kidney disease requiring renal replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andra I Duncan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel I Sessler, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Schricker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Victoria Hospital, Montreal, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Carvalho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Victoria Hospital, Montreal, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Albacker TB, Carvalho G, Schricker T, Lachapelle K. Myocardial protection during elective coronary artery bypass grafting using high-dose insulin therapy. Ann Thorac Surg. 2007 Dec;84(6):1920-7; discussion 1920-7.</citation>
    <PMID>18036907</PMID>
  </results_reference>
  <results_reference>
    <citation>Duncan AE, Kateby Kashy B, Sarwar S, Singh A, Stenina-Adognravi O, Christoffersen S, Alfirevic A, Sale S, Yang D, Thomas JD, Gillinov M, Sessler DI. Hyperinsulinemic Normoglycemia Does Not Meaningfully Improve Myocardial Performance during Cardiac Surgery: A Randomized Trial. Anesthesiology. 2015 Aug;123(2):272-87. doi: 10.1097/ALN.0000000000000723.</citation>
    <PMID>26200180</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <results_first_submitted>March 7, 2017</results_first_submitted>
  <results_first_submitted_qc>February 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2018</results_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperinsulinemic glucose control</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>Outcome</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hyperinsulinemic-normoglycemic Clamp</title>
          <description>Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
Hyperinsulinemic-normoglycemic clamp: Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.</description>
        </group>
        <group group_id="P2">
          <title>Insulin at the Standard of Care Levels</title>
          <description>Group B will be administered insulin at the standard of care levels established by the participating institution.
insulin at the standard of care levels: Subjects will be administered insulin at the standard of care levels established by the participating institution.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="709"/>
                <participants group_id="P2" count="730"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="709"/>
                <participants group_id="P2" count="730"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hyperinsulinemic-normoglycemic Clamp</title>
          <description>Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
Hyperinsulinemic-normoglycemic clamp: Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.</description>
        </group>
        <group group_id="B2">
          <title>Insulin at the Standard of Care Levels</title>
          <description>Group B will be administered insulin at the standard of care levels established by the participating institution.
insulin at the standard of care levels: Subjects will be administered insulin at the standard of care levels established by the participating institution.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="709"/>
            <count group_id="B2" value="730"/>
            <count group_id="B3" value="1439"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="11"/>
                    <measurement group_id="B2" value="66" spread="11"/>
                    <measurement group_id="B3" value="66" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="373"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="520"/>
                    <measurement group_id="B2" value="546"/>
                    <measurement group_id="B3" value="1066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="457"/>
                    <measurement group_id="B2" value="464"/>
                    <measurement group_id="B3" value="921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="266"/>
                    <measurement group_id="B3" value="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Any Major Morbidity/30-day Mortality</title>
        <description>a composite (any versus none) of the following major postoperative complications occurring:
all-cause postoperative mortality
failure to wean from cardiopulmonary bypass or postoperative low cardiac index requiring mechanical circulatory support with intraaortic balloon counterpulsation, ventricular assist device, and/or extracorporeal mechanical oxygenation
serious postoperative infection
acute postoperative kidney injury requiring renal replacement therapy;
new postoperative focal or global neurologic deficit.</description>
        <time_frame>within 30 days post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hyperinsulinemic-normoglycemic Clamp</title>
            <description>Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
Hyperinsulinemic-normoglycemic clamp: Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin at the Standard of Care Levels</title>
            <description>Group B will be administered insulin at the standard of care levels established by the participating institution.
insulin at the standard of care levels: Subjects will be administered insulin at the standard of care levels established by the participating institution.</description>
          </group>
        </group_list>
        <measure>
          <title>Any Major Morbidity/30-day Mortality</title>
          <description>a composite (any versus none) of the following major postoperative complications occurring:
all-cause postoperative mortality
failure to wean from cardiopulmonary bypass or postoperative low cardiac index requiring mechanical circulatory support with intraaortic balloon counterpulsation, ventricular assist device, and/or extracorporeal mechanical oxygenation
serious postoperative infection
acute postoperative kidney injury requiring renal replacement therapy;
new postoperative focal or global neurologic deficit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="709"/>
                <count group_id="O2" value="730"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0043</p_value>
            <p_value_desc>P-values for combined sites: significant if P &lt; 0.0085 for efficacy. Adjusted for interim analysis.
Confidence intervals adjusted for interim analysis.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>Hyperinsulinemic-normoglycemic clamp</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Atrial Fibrillation</title>
        <description>Evidence suggests that maintaining intra-operative normoglycemia during cardiac surgery while providing exogenous glucose and high-dose insulin may decrease post-operative morbidity or mortality. Using a randomized, controlled design, we propose to test the primary hypothesis that normalization of blood glucose using a hyperinsulinemic-normoglycemic clamp technique reduces the risk of a composite of serious adverse outcomes in patients undergoing cardiac surgery</description>
        <time_frame>15 - 30 days post operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hyperinsulinemic-normoglycemic Clamp</title>
            <description>Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
Hyperinsulinemic-normoglycemic clamp: Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin at the Standard of Care Levels</title>
            <description>Group B will be administered insulin at the standard of care levels established by the participating institution.
insulin at the standard of care levels: Subjects will be administered insulin at the standard of care levels established by the participating institution.</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Atrial Fibrillation</title>
          <description>Evidence suggests that maintaining intra-operative normoglycemia during cardiac surgery while providing exogenous glucose and high-dose insulin may decrease post-operative morbidity or mortality. Using a randomized, controlled design, we propose to test the primary hypothesis that normalization of blood glucose using a hyperinsulinemic-normoglycemic clamp technique reduces the risk of a composite of serious adverse outcomes in patients undergoing cardiac surgery</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="709"/>
                <count group_id="O2" value="730"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>HN vs. standard</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization</title>
        <description>Days from date of surgery to hospital discharge</description>
        <time_frame>starting post operative day one to discharge from hospital, on an average of 8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hyperinsulinemic-normoglycemic Clamp</title>
            <description>Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
Hyperinsulinemic-normoglycemic clamp: Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin at the Standard of Care Levels</title>
            <description>Group B will be administered insulin at the standard of care levels established by the participating institution.
insulin at the standard of care levels: Subjects will be administered insulin at the standard of care levels established by the participating institution.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization</title>
          <description>Days from date of surgery to hospital discharge</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="686"/>
                <count group_id="O2" value="713"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="12"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Intensive Care Stay</title>
        <description>Hours from date of surgery to discharge from intensive care unit</description>
        <time_frame>ICU stay hours during hospital stay after surgery, on average of 25 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hyperinsulinemic-normoglycemic Clamp</title>
            <description>Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
Hyperinsulinemic-normoglycemic clamp: Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin at the Standard of Care Levels</title>
            <description>Group B will be administered insulin at the standard of care levels established by the participating institution.
insulin at the standard of care levels: Subjects will be administered insulin at the standard of care levels established by the participating institution.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Intensive Care Stay</title>
          <description>Hours from date of surgery to discharge from intensive care unit</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="649"/>
                <count group_id="O2" value="671"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="24.9" upper_limit="26.3"/>
                    <measurement group_id="O2" value="27" lower_limit="25.2" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Regression, Cox</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>HN vs. Standard</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <description>All-cause mortality identified during one-year follow-up.</description>
        <time_frame>one year post operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hyperinsulinemic-normoglycemic Clamp</title>
            <description>Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
Hyperinsulinemic-normoglycemic clamp: Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin at the Standard of Care Levels</title>
            <description>Group B will be administered insulin at the standard of care levels established by the participating institution.
insulin at the standard of care levels: Subjects will be administered insulin at the standard of care levels established by the participating institution.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <description>All-cause mortality identified during one-year follow-up.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="653"/>
                <count group_id="O2" value="682"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>3.11</ci_upper_limit>
            <estimate_desc>HN vs. standard</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>a Composite of Minor Postoperative Complications</title>
        <description>a composite of minor postoperative complications, which includes: a) prolonged mechanical ventilation, b) low cardiac index, c) acute kidney injury, d) prolonged hospitalization, and 3) all-cause hospital readmission within 30 days.</description>
        <time_frame>within 30 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hyperinsulinemic-normoglycemic Clamp</title>
            <description>Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
Hyperinsulinemic-normoglycemic clamp: Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin at the Standard of Care Levels</title>
            <description>Group B will be administered insulin at the standard of care levels established by the participating institution.
insulin at the standard of care levels: Subjects will be administered insulin at the standard of care levels established by the participating institution.</description>
          </group>
        </group_list>
        <measure>
          <title>a Composite of Minor Postoperative Complications</title>
          <description>a composite of minor postoperative complications, which includes: a) prolonged mechanical ventilation, b) low cardiac index, c) acute kidney injury, d) prolonged hospitalization, and 3) all-cause hospital readmission within 30 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="709"/>
                <count group_id="O2" value="730"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>HN vs. Standard</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One Year Post-opeperative follow-up for All-Cause Mortality; 1 month Post-opeperative follow-up for Serious Adverse Events and Other (Not Including Serious) Adverse Events</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hyperinsulinemic-normoglycemic Clamp</title>
          <description>Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
Hyperinsulinemic-normoglycemic clamp: Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.</description>
        </group>
        <group group_id="E2">
          <title>Insulin at the Standard of Care Levels</title>
          <description>Group B will be administered insulin at the standard of care levels established by the participating institution.
insulin at the standard of care levels: Subjects will be administered insulin at the standard of care levels established by the participating institution.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="730"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="730"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>sae</sub_title>
                <description>Adverse Events were monitored/assessed without regard to the specific Adverse Event Term</description>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="709"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="730"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="730"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andra Duncan, MD</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216 445-2372</phone>
      <email>DUNCANA@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

